bioAffinity Technologies to Host Live Virtual Physician Roundtable on Integrating CyPath® Lung into Pulmonary Practice
MWN-AI** Summary
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a pioneering biotechnology company focused on noninvasive cancer diagnostics, is set to host a live virtual physician roundtable titled "CyPath® Lung in Practice." Scheduled for April 8, 2026, at 7 p.m. ET, this initial webinar will feature a panel of renowned pulmonologists discussing the integration of the CyPath® Lung diagnostic test within clinical pulmonary practice.
CyPath® Lung is designed to enhance early lung cancer detection in high-risk patients by utilizing advanced flow cytometry and proprietary AI to identify malignant cell populations in sputum samples. Clinical studies have demonstrated its impressive 92% sensitivity and 87% specificity when identifying lung cancer in patients with small indeterminate nodules.
The interactive roundtable aims to address the pressing need for reliable diagnostics for pulmonary nodules, with physicians presenting real-world cases that illustrate CyPath® Lung’s utility in clinical decision-making. These cases will highlight its effectiveness in diagnosing lung cancer at an early stage and minimizing unnecessary invasive procedures by providing clear malignancy risk guidelines.
Healthcare professionals interested in integrating the CyPath® Lung test into their practices can register for the free webinar. The session will be moderated by Dr. Gordon H. Downie, Chief Medical Officer at bioAffinity Technologies, and will feature notable experts, including Dr. Sai Karan Vamsi Guda, Dr. Michael Nicholson, and Dr. Gregory White, who will share valuable insights and practical knowledge.
BioAffinity Technologies continues to address the intricacies of early-stage cancer diagnoses, aiming to reshape the landscape of pulmonary care with innovative, noninvasive solutions. Interested parties can learn more by visiting their website and registering for the roundtable discussion.
MWN-AI** Analysis
bioAffinity Technologies is poised to strengthen its position in the biotech sector with its upcoming virtual physician roundtable centered on the innovative CyPath® Lung diagnostic test. As a financial analyst, I see this initiative as a strategic move to enhance medical professionals’ understanding and usage of their noninvasive analytics tool, which could lead to increased adoption and sales.
The live webinar, set for April 8, 2026, will showcase real-world applications of CyPath® Lung, especially its efficacy in detecting early-stage lung cancer and reducing unnecessary invasive procedures. Such discussions within the medical community can foster trust and credibility, key factors in driving product adoption among healthcare professionals. As the healthcare market increasingly shifts towards noninvasive solutions, bioAffinity’s focus on early detection is well-timed, potentially aligning with broader trends in patient-centered care.
From an investment perspective, it’s important to monitor the adoption rates following the webinar. If CyPath® Lung can demonstrate real clinical utility, we might see a positive impact on revenue growth and potentially boost stock performance. Its current metrics—92% sensitivity and 87% specificity—underscore its diagnostic value. However, concerns regarding the commercialization process and regulatory approval remain, requiring close scrutiny.
Investors should diversify risk by keeping track of any developments that may signal increased adoption or improvements in clinical outcomes stemming from CyPath® Lung use. Paying attention to pilot studies, peer-reviewed publications, and customer testimonials post-webinar could offer vital insights into the product’s reception in the clinical environment.
In conclusion, while bioAffinity Technologies presents potential growth opportunities through innovations like CyPath® Lung, cautious optimism is warranted. Observational diligence regarding adoption and market penetration will serve as a guiding strategy for stakeholders considering investment in this promising biotech firm.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Panel of leading pulmonologists will share real-world patient cases and benefits of clinical use of the noninvasive CyPath® Lung diagnostic test
First of “CyPath® Lung in Practice” webinar series focuses on need for greater certainty when diagnosing indeterminate pulmonary nodules
Healthcare providers can register here for the April 8, 2026, webinar
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) , a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced it will host the first of a series of live virtual physician roundtables featuring pulmonologists who will discuss their use of CyPath® Lung in clinical practice as part of a comprehensive approach to lung cancer risk assessment, pulmonary nodule management and surveillance of lung cancer survivors post-treatment.
During the webinar, participating physicians will share real-world case studies in which CyPath® Lung helped guide clinical decision-making. Cases that demonstrate CyPath® Lung’s clinical utility range from identifying lung cancer at Stage 1A when it is curative to preventing unnecessary invasive, risky and costly procedures when CyPath® Lung resulted in “Unlikely” malignancy.
The interactive session will provide pulmonologists and other healthcare professionals with practical insights into adding CyPath® Lung to the diagnostic pathway for patients at high risk for lung cancer. Healthcare professionals interested in learning how CyPath® Lung can be incorporated into pulmonary practice are encouraged to register.
Webinar Details
Title: CyPath® Lung in Practice: A Physician Roundtable Discussion
Format: Live Zoom webinar. The webinar will be recorded and posted on the CyPath® Lung website .
Date/Time: Wednesday, April 8, 2026 , at 7 p.m. ET/6 p.m. CT.
Registration: https://bit.ly/4ruhbJO
Moderator: Gordon H. Downie, MD, PhD
Pulmonologist and Chief Medical Officer of bioAffinity Technologies with more than 35 years of experience in pulmonary and critical care medicine and lung cancer diagnostics.
Panelists:
- Sai Karan Vamsi Guda, DO
Interventional pulmonologist with Texas Pulmonary & Critical Care Consultants in Fort Worth specializing in robotic bronchoscopy, airway stenting, and minimally invasive diagnosis and treatment of lung disease. - Michael Nicholson, DO
Pulmonologist and critical care specialist with RWJBarnabas Health Medical Group in New Jersey with expertise in advanced lung disease and a clinical focus on enhancing noninvasive malignancy risk stratification in patients with pulmonary nodules. - Gregory White, MD
Pulmonologist at CHRISTUS Trinity Clinic specializing in comprehensive pulmonary care, including advanced bronchoscopy and treatment of lung cancer, asthma, and COPD, with a patient-focused, personalized approach.
About CyPath® Lung
CyPath® Lung by bioAffinity Technologies is a noninvasive test designed to aid in the early detection of lung cancer in patients at high risk for the disease. CyPath® Lung uses advanced flow cytometry and proprietary artificial intelligence (AI) to identify cell populations in patient sputum that may indicate malignancy. CyPath® Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. Clinical study results demonstrated 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small indeterminate lung nodules less than 20 millimeters.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath® Lung , is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services , a subsidiary of bioAffinity Technologies. LDTs are overseen under the Clinical Laboratory Improvement Amendments (CLIA), administered by the Centers for Medicare & Medicaid Services. For more information, visit www.bioaffinitytech.com .
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to successfully commercialize CyPath® Lung, the adoption of CyPath® Lung by physicians and healthcare providers, the Company’s ability to obtain and maintain regulatory approvals, and the other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260325106814/en/
bioAffinity Technologies
Julie Anne Overton
Director of Communications
investors@bioaffinitytech.com
FAQ**
How does the performance of CyPath® Lung compare with traditional diagnostic methods for patients with indeterminate pulmonary nodules in terms of accuracy and reliability, specifically for the bioAffinity Technologies Inc. Warrant BIAFW?
What strategies does bioAffinity Technologies Inc. plan to implement to ensure widespread adoption of CyPath® Lung among healthcare providers, and how might this impact the value of their stock and the bioAffinity Technologies Inc. Warrant BIAFW?
In what ways will the insights shared during the "CyPath® Lung in Practice" webinar potentially influence the market perception of bioAffinity Technologies Inc., particularly concerning the bioAffinity Technologies Inc. Warrant BIAFW?
Given the clinical trial results showcasing 92% sensitivity and 87% specificity, what challenges might bioAffinity Technologies Inc. face in commercializing CyPath® Lung, and how could these challenges affect the bioAffinity Technologies Inc. Warrant BIAFW?
**MWN-AI FAQ is based on asking OpenAI questions about bioAffinity Technologies Inc. Warrant (NASDAQ: BIAFW).
NASDAQ: BIAFW
BIAFW Trading
43.02% G/L:
$0.4525 Last:
11,164 Volume:
$0.3395 Open:
